Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 12/20 | 0.46 |
| ▸ | CA9 | Q16790 | 12/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 10/20 | 0.44 |
| ▸ | CA2 | P00918 | 10/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700836 | 0.82 | LMNA (0.47) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL692624 | 0.79 | LMNA (0.61) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL17897700 | 0.78 | LMNA (0.54) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL1700856 | 0.76 | SMN1; SMN2 (0.42) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL17791229 | 0.76 | CYP1A2 (0.49) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL10508539 | 0.74 | LMNA (0.53) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL8551272 | 0.72 | LMNA (0.54) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL21129745 | 0.72 | LMNA (0.51) | LMNAKMT2AKDM4ECYP1A2GRIA1 | |
| SCHEMBL1700460 | 0.71 | NPSR1 (0.44) | KDM4ENPSR1NPC1RAB9A | |
| SCHEMBL24360209 | 0.71 | LMNA (0.56) | LMNAKMT2AKDM4ECYP1A2GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566334-B1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| CN-103025164-B | The control release of medicine from solid support | 普罗林科斯有限责任公司 | 2017-03-08 | — | — | CN | disclosed |
| EP-2566335-B1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| CN-103025165-B | From the controlled release of macromolecular conjugates | 普罗林科斯有限责任公司 | 2016-06-08 | — | — | CN | disclosed |
| US-8946405-B2 | Controlled release from solid supports | PROLYNX LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-8754190-B2 | Controlled release from macromolecular conjugates | PROLYNX LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8703907-B2 | Controlled drug release from dendrimers | PROLYNX LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130123487-A1 | CONTROLLED RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130116407-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC | 2013-05-09 | — | — | US | disclosed |
| CN-103025165-A | Controlled release from macromolecular conjugates | PROLYNX LLC | 2013-04-03 | — | — | CN | disclosed |
| CN-103025164-A | Controlled drug release from solid supports | PROLYNX LLC | 2013-04-03 | — | — | CN | disclosed |
| EP-2571496-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | Prolynx Llc (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2566334-A1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | Prolynx Llc (US) | 2013-03-13 | — | — | EP | disclosed |
| EP-2566335-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | Prolynx Llc (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140376-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140393-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140392-A1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123487-A1 | CONTROLLED RELEASE FROM SOLID SUPPORTS | SLC43A1, ABCB1, NAPA | LMNA 1325/4885KMT2A 2288/4885KDM4E 2803/4885 |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | SLC43A1, SLC47A1, SLC47A2 | LMNA 1267/4885KMT2A 3288/4885KDM4E 3717/4885 |
| US-20130116407-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | ABCB1, ABCB11, GUSB | LMNA 2174/4885KMT2A 3975/4885KDM4E 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.